Styliani Karanika

A DNA vaccine targeting Mtb persisters reduces TB treatment duration in mice and elicits similar immune responses in macaques.

This paper develops an anti-CCRL2 antibody-drug conjugate (ADC) that shows potent cytotoxicity against high-risk MDS/AML cells without harming healthy hematopoietic cells.

This study shows that an intranasal DNA vaccine targeting RelMtb with MIP3α induces T-cell infiltration in the lungs of mice and macaques, enhancing immune responses against Mtb.

This study shows that targeting CCRL2 with an antibody-drug conjugate improves TB treatment in mice by reducing inflammation and enhancing immune responses.

This study identifies CCRL2 as a driver of IFN-γ signaling in TP53-mutated AML with erythroid differentiation, linking it to disease progression and poor outcomes.

This study evaluates two compounds that reduce triglyceride content in Mtb-infected macrophages but finds they do not reduce bacterial burden or inflammation in infected mice.

This paper evaluates the adjunctive effect of the HO-1 inhibitor stannsoporfin in combination with a novel MDR-TB regimen in a murine model, showing reduced lung bacillary burden but no effect on microbiological relapse.